Critiquing: Amelia’s family ‘mislead by cancer clinic’

6/5/2013 – This article was published By Getreading [1]

“A family who sent their terminally ill daughter to the US for experimental treatment said the clinic misled them about her chances of survival

“The parents of Pride of Reading Child of Courage winner, four-year-old Amelia Saunders who died in January, say they were told she had a 54 per cent chance of survival with the clinical trial in Houston, Texas

“However mum Chantal Saunders, 36, believes the actual figure was just one per cent
——————————————————————
Based on what ?
——————————————————————
“A BBC Panorama investigation shown on Monday questioned whether the Burzynski Clinic was “selling hope” to families
——————————————————————
Aren’t all cancer treatments “selling hope” ?
——————————————————————
“In it, Mrs Saunders said:”

“I think that’s wrong” [54 per cent figure]

“I think that’s a complete lie”

“I think one per cent is a more accurate figure.”
——————————————————————
Based on what ?
——————————————————————
“Dad Richard, 35, says he has only found two patients of Dr Stanislaw Burzynski with the same rare brain tumour as Amelia who survived long-term”

“Mr Saunders, from Lower Earley, said:”

“It didn’t work for Amelia but we absolutely know it works for other people.”

“It’s hard to believe it works for Amelia’s tumour type and that’s what we have found tricky”

“I’ve had all sorts of excuses from them as to why they won’t release data on how many patients they treat and the outcomes”

“I think the figures Panorama were given show there was 700-odd patients they treated and something like 15 per cent survived over five years
——————————————————————
Panorama’s figures were:

“They say 776 patients with brain tumours were treated in trials before 2008.”

“And that 15.5% had survived more than five years, which compares favourably to other treatments.” [2]
——————————————————————
“If you look at all brain tumours that’s almost identical to any other treatment”
——————————————————————
Based on what ?
——————————————————————
“If you look at Amelia’s tumour alone you’re looking at almost zero per cent.”

Amelia was diagnosed with a rare tumour on her brain stem in February last year

“Her devastated family was told by doctors there was no treatment available in Britain”

“After finding out about Burzynski’s clinical trial, which has been running for 20 years, Amelia’s family decided to raise the money needed for the ‘antineoplaston’ treatment – a staggering £250,000 – in just a few weeks through donations”

Mrs Saunders, who also has two-year-old daughter Charlotte, said:”

“He was giving us more hope than I think realistically there was”
——————————————————————
Based on what ?
——————————————————————
Mr Saunders added:”

“We find it very hard to believe the treatment did nothing”

“We did no chemotherapy with her”

“To keep it stable for 11 months is incredible in itself, but how do we prove that?”

“We can’t.”
——————————————————————
Why not ?

Were there not scans ?
——————————————————————
“In November last year Dr Burzynski told the family a new scan showed Amelia’s tumour was breaking down

UK doctors at Great Ormond Street Hospital in London said it actually showed the tumour was continuing to grow
——————————————————————
Based on what ?

Great Ormond Street Hospital having 36 years of experience treating patients with antineoplastons ?
——————————————————————
“The family decided to stop the Burzynski treatment a few weeks later”
——————————————————————
Based on what ?
——————————————————————
“Although the family now has doubts over Burzynski’s success rate, Richard says they have spoken to others who have been helped by the drug”
——————————————————————
“The family now has doubts over Burzynski’s success rate” ?

What was all this, then ?

a) “A family who sent their terminally ill daughter to the US for experimental treatment said the clinic misled them about her chances of survival

b) “However mum Chantal Saunders, 36, believes the actual figure was just one per cent

c) “I think that’s wrong” [54 per cent figure]

“I think that’s a complete lie”

d) “I think one per cent is a more accurate figure.”

e) “He was giving us more hope than I think realistically there was”
——————————————————————
“He said:”

“We asked repeatedly throughout the time Amelia was under treatment for evidence to back up his claims, and he at no point produced this”

“We found patients ourselves through Facebook, forums, email and word of mouth”

“We want everyone to know that there are people who are living proof that the treatment works – but it just didn’t for our little girl”

“We just wish Dr Burzynski would speak the truth, and release proper, tangible results.”
——————————————————————
So, you wanted him to “release proper, tangible results” before the clinical trials were finished ?
——————————————————————
“The Saunders family have donated the rest of the money raised for Amelia to cancer research and other charities”

“This included £50,000 to a cancer treatment research team at the University of Nottingham

“Its Professor Richard Grundy said it was “unethical” for Dr Burzynski not to publish results from his trial
——————————————————————
So, you wanted him to “publish results from his trial” before the clinical trial was finished ?
——————————————————————
“Unfortunately the results from Dr Burzynski’s clinic are not published in any form that’s acceptable to the scientific community,” he said”
——————————————————————
So a donation of £50,000 was made, which included to a cancer treatment research team at the University of Nottingham, where Professor Richard Grundy; who exhibits NO knowledge of antineoplastons in this article, is

How “convenient” for him and the University

In my opinion,’ it is “unethical” for Professor Grundy to NOT share his findings re Dr. Burzynski’s 2003-2010 phase 2 clinical trial preliminary reports [3]

He reminds of the situation that Burzynski found himself in when he relates that clinical investigators decided to change the protocol without his approval on a clinical trial of antineoplastons

Seriously, who in their right mind would ignore the input of the inventor and developer of a medicine with close to 20 years of clinical experience, and think they know more than that person ? [4]
======================================
REFERENCES:
======================================
[1] – Reading Post, Amelia’s family ‘mislead by cancer clinic’, By Getreading | 5 Jun 2013 07:59
——————————————————————
http://www.getreading.co.uk/news/amelia-saunders-family-mislead-burzynski-4051287
======================================
[2] – 8/4/2013 – Critiquing Dr David H. “Orac” Gorski, M.D., Ph.D, LIAR: Stanislaw Burzynski versus the BBC:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/04/critiquing-dr-david-h-orac-gorski-m-d-ph-d-liar-stanislaw-burzynski-versus-the-bbc/
======================================
[3] – 9/22/2013 – Critiquing Wikipedia: Burzynski Clinic – 2013 BBC documentary, Curing cancer or ‘selling hope’ to the vulnerable?;
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/22/critiquing-wikipedia-burzynski-clinic-2013-bbc-documentary-curing-cancer-or-selling-hope-to-the-vulnerable/
======================================
[4] – Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet “fact sheet”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/19/critiquing-national-cancer-institute-nci-at-the-national-institutes-of-health-nih-cancernet/
======================================

Advertisements

Critiquing: Watford Observer – ‘He said he hoped to cure my daughter’

6/7/2013 the Watford Observer published this article By Kathryn Snowdon [1]

“The mother of Luna Petagine has cast doubt on the expensive treatment the family sought in America during the Oxhey girl’s four-year battle with cancer
——————————————————————
Expensive treatment,” based on what objective criteria ? [2]
——————————————————————
BBC Panorama this week aired an investigation into Doctor Stanislaw Burzynski’s cancer clinic in Texas, where hundreds of children – normally terminally ill – go and seek treatment”

“Luna, who was five-years-old when she died last year, was a patient at The Burzynski Clinic after her parents were told the physician could cure their daughter, despite Great Ormond Street Hospital doctors saying little more could be done for her”
——————————————————————
Why the conflicting statements ?

a) “her parents were told the physician could cure their daughter”

b) “The NHS are telling me my daughter’s going to die and this man is telling me that he thinks he can cure her.”

c) “He said he hoped to cure my daughter

d) “The plan was to try and cure Luna.”
——————————————————————
Luna’s mother, Lucy Petagine, of Raglan Gardens, said there was no doubt in her mind she was going to send her daughter to Dr Burzynski

“Mrs Petagine said:”

“Of course I’m going to go with him

If anyone had knocked on my door and said

‘here if you try this it will work’

“then yeah I would have tried it because I was in desperation”

“The NHS are telling me my daughter’s going to die and this man is telling me that he thinks he can cure her.”

“Mrs Petagine added:”

“It was all about hope

He said he hoped to cure my daughter

The plan was to try and cure Luna.”

“In order to finance the treatment, which the family believed could be life-saving, more than £100,000 was raised and in September 2011 they travelled to America”

“However, Mrs Petagine said the treatment at The Burzynski Clinic was actually killing her daughter

“She added:”

The treatment was – what was happening – was actually killing Luna because it put this pressure on her brain stem.”
——————————————————————
Why did Mrs Petagine say that “the treatment at The Burzynski Clinic”“was actually killing Luna” ?

Did someone tell her this, or was this her personal opinion ?

We know from Burzynski’s 3/2004 publication that:

“The reason for 50% Progressive Disease (PD) in studies is long dose-escalation process, which extends to more than a month’s time period, before the optimal dosage is reached” [3]
——————————————————————
“In response to Panorama’s questioning and claims that he was merely selling hope to vulnerable families, Dr Burzynski said:”

“Can you imagine that the US government… they would allow me to be here if I just sell hope?”
——————————————————————
Isn’t every cancer treatment “selling hope to vulnerable families”?

Isn’t every cancer clinical trial “selling hope to vulnerable families” ?
——————————————————————
“The treatment has not been approved by the American Food and Drug Administration (FDA)
——————————————————————
12/2008 – Burzynski’s publication advised:

“In 2004 the FDA granted orphan drug designation for antineoplastons A10 and AS2-1 for the treatment of brainstem glioma” [4]

9/2012“The FDA granted Orphan Drug designation for Antineoplastons A10 and AS2-1 for the treatment of gliomas, in 2009″ [5]
——————————————————————
“A month into Luna’s therapy, an MRI revealed the tumour had grown, pressing on Luna’s brain stem and causing her breathing problems and facial palsy”

Mrs Petagine said:”

“They said the tumour’s grown and we were like ‘how could it have grown this quickly, this doesn’t make sense’.”
——————————————————————
What does Mrs Petagine mean when she said:

‘how could it have grown this quickly, this doesn’t make sense’ ?

We know from [3] above, that the tumor is likely to grow before the medicine has reached it’s optimal dosage, and the tumor starts to decrease in size
——————————————————————
Luna had to be admitted to intensive care in Texas Children’s Hospital

Mrs Petagine said:”

Texas Children’s hate The Burzynski Clinic

“They said they have to clean up all his mess”

“The second you walk in the door they look at your child and they did actually say to us ‘are you a Burzynski family?’”
——————————————————————
If Texas Children’s actually does that with every child patient that comes in the door, that would be a really stupid bias to foist on some unsuspecting parent
——————————————————————
“Luna died in August last year”
——————————————————————
Unfortunately, the article does not tell the reader what happened ?

Was Luna taken off of antineoplaston therapy?

Or was she still on the treatment when she unfortunately passed ?
======================================
REFERENCES:
======================================
[1] – 9:50am Friday 7th June 2013, By Kathryn Snowdon
——————————————————————
http://www.watfordobserver.co.uk/news/10470494.print/
======================================
[2] – 9/22/2013 – Critiquing Wikipedia: Burzynski Clinic – 2013 BBC documentary, Curing cancer or ‘selling hope’ to the vulnerable?
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/22/critiquing-wikipedia-burzynski-clinic-2013-bbc-documentary-curing-cancer-or-selling-hope-to-the-vulnerable/
======================================
[3] – Review Articles on Clinical Trials:

1. 3/2004 – The Present State of Antineoplaston Research
——————————————————————
Integrative Cancer Therapies 2004;3:47-58
Volume 3, No. 1, March 2004

DOI: 10.1177/1534735-403261964

Volume 3 Number 1.March.2004

Pg. 50
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/994.pdf
======================================
[4] – 12/2008 – Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Neuro-Oncology 2008; 10:1148

Volume 10 Issue 6.December.2008
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/7897.pdf
======================================
[5] – 9/2012 – Patil, S., Burzynski S.R., Mrowczynski, E., Grela, K. P.003. Phenylacetylglutaminate in combination with Phenylbutyrate effectively inhibits growth of brain tumor cell In Vitro. Neuro-Oncology 2012;14(Suppl. 3):iii16

Volume 14 Supplement 3 September 2012
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/9291.pdf
======================================

Critiquing: Dr. David H. “Orac” Gorski, M.D., Ph.D, LIAR: Stanislaw Burzynski versus the BBC

Believe in Facts ???

Get out the popcorn !!!
——————————————————————
Dr. David H. “Orac” Gorski is a liar

Let me put that in bold for emphasis

Dr. David H. “Orac” Gorski is a liar

Open wide and say ahhhhhhh …

DR. DAVID H. “ORAC” GORSKI IS A LIAR
——————————————————————
Much better !!!

Some things just look much better when they come in 3’s

And that must be what “Orac” is god thinks, since he seems to live by the the edict of the 3 wise monkeys:
——————————————————————
See No Evil

Hear No Evil

Speak No Evil
——————————————————————
Of course, to Gorski, Evil is any truth which he disagrees with, which he acts like does NOT exist, and obviously can NOT find on the Internet with his Commodore 64, or whatever piece of garbage he’s using, which he must have set to block any websites he wishes to NOT see
——————————————————————
Gorski, the Hypocrite, calls me a “CRANK”, which is especially hilarious, considering how much better my research is than his, without the bias

LIES

Misdirection

Disinformation

Misinformation

MisDisInformation
——————————————————————
David Gorski (@gorskon) tweeted at 3:24am – 14 Jul 13:

@Funkmon @HoracioHornblow Ha ha. It’s the rather pathetic crank Didymus Judas Thomas. That guy couldn’t buy a clue. #Burzynski

——————————————————————
If I wanted to lower myself to Gorski’s level, I could delete comments from my blog
——————————————————————
6/4/2013, Gorski must have evacuated this from deep within his bowels:
� � � � � � � � � � � � � � � �
Stanislaw Burzynski versus the BBC
http://scienceblogs.com/insolence/2013/06/04/stanislaw-burzynski-versus-the-bbc/
� � � � � � � � � � � � � � � �
I was busy at the time reviewing the British Broadcasting Corporation’s Panorama bit on Burzynski:
======================================
6/4/2013

The British are Coming, The British are Coming: Critiquing “Curing cancer or ‘selling hope’ to the vulnerable?”:
https://stanislawrajmundburzynski.wordpress.com/2013/06/04/the-british-are-coming-the-british-are-coming-critiquing-curing-cancer-or-selling-hope-to-the-vulnerable/
======================================
6/7/2013

IT MAY NOT BE SCIENCE: Critiquing “Curing cancer or ‘selling hope’ to the vulnerable?”:
https://stanislawrajmundburzynski.wordpress.com/2013/06/07/it-may-not-be-science-critiquing-curing-cancer-or-selling-hope-to-the-vulnerable/
======================================
But now that I have some time, lets all enjoy Gorski’s LIES

Misdirection

Disinformation

Misinformation

MisDisInformation

While I DISS his MisDisInformation

Since the dates involved are important in exposing Gorski’s LIES, Gorski states:
——————————————————————
“After yesterday’s epic deconstruction of the latest propaganda-fest from … Eric Merola, on his most admired subject, “brave maverick doctor” Stanislaw Burzynski”
——————————————————————
(6/3/2013) in relation to Gorski’s cherry-picked “review” which I critiqued:
======================================
7/18/2013

Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
======================================
Gorski posits:
——————————————————————
“I needed something science-based to cleanse the rancid taste of intelligence-insulting nonsense from my mind”
——————————————————————
My understanding of Gorski’s definition of #ScienceBasedMedicine is:

1. Visualize a Victim

2. Create biased blogposts utilizing:

a. LIES

b. Misdirection

c. Disinformation

d. Misinformation

e. MisDisInformation

Gorski advises:
——————————————————————
“I was interviewed over the phone by a producer of the show and exchanged e-mails to answer questions”
——————————————————————
I am NOT certain what qualifications BBC Panorama thought that Gorski has in order for him to be interviewed about Burzynski, unless they wanted the perspective of a LIAR

Gorski mentions “False balance”, which readers of his and / or my blog are all too familiar with when it comes to “Orac”

He whines that there is:
——————————————————————
” … zero mention of how Burzynski recently managed to beat an effort by the Texas Medical Board to strip him of his medical license by throwing his employed doctors under the bus …”
——————————————————————
This seems to be:

Misdirection

Disinformation

Misinformation

by Gorski, as anyone can read the case documents:
======================================
Burzynski: Texas Medical Board (TMB) and State Office of Administrative Hearings (SOAH):
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/burzynski-texas-medical-board-tmb-and-state-office-of-administrative-hearings-soah/
======================================
and note that, as Richard A. Jaffe points out, Burzynski was:

1. NOT even in the USA during one of the patients care

2. there was no evidence that Burzynski met either patient

3. Burzynski was NOT the Doctor of Record for either patient

4. If the SOAH had an actual case, they could have gone after the actual Doctors of Record

What Gorski blogs is NOT worth the paper it is NOT written on

EVERYTHING Gorski blogs should be “Fact-Checked” for accuracy

He also ejects:
——————————————————————
” … only the most superficial treatment of how in general it is considered unethical to demand payment from patients to participate in clinical trials”
——————————————————————
though he provides NO basis in FACT for this statement

He also laments:
——————————————————————
“No, and there isn’t any mention of how the Burzynski Clinic waged a campaign of harassment against bloggers who criticized Burzynski back in 2011”
——————————————————————
What Gorski does NOT mention is that:

there isn’t any mention of how the bloggers waged a campaign of harassment against Burzynski

with their:

LIES

Misdirection

Disinformation

Misinformation
======================================
I find Rhys Morgan abnormally prehensile:
https://stanislawrajmundburzynski.wordpress.com/2013/04/20/i-find-rhys-morgan-abnormally-prehensile/
======================================
Gorski cries:
——————————————————————
“Indeed, one of the victims of that harassment, Rhys Morgan, was interviewed by the Panorama crew, but he was informed that his interview was cut from the final version because it didn’t fit the narrative”
——————————————————————
I thought it humorous when The Skeptics™ whined on Twitter that Rhys Morgan wasn’t going to make the cut

What was he going to say ?

How he copied all of his Burzynski blogsplats from other people’s blogs?

Gorski mentions:
——————————————————————
“All you have to do is to read Saul Green’s reports on Quackwatch and in The Cancer Letter from the 1990s”
——————————————————————
Of course, Gorski conveniently forgets to mention Green’s Confict-of-Interest, since Green was associated with a lawsuit against Burzynski

But then again, Gorski seems to have conveniently forgotten his own possible COI, which someone posted a link to on Twitter:
——————————————————————
David Gorski’s Financial PHARMA Ties What He Didn’t Tell You:
http://www.ageofautism.com/2010/06/david-gorskis-financial-pharma-ties-what-he-didnt-tell-you.html
——————————————————————
Gorski fumes:
——————————————————————
“One of them reminded me very much of the conversation with her NHS oncologist that Laura Hymas recorded and allowed Eric Merola to include in his propaganda piece, except that in video it is so much more intense”

“In this scene, the oncologist tries to point out to Ms. Petagine that he doesn’t know what Burzynski is doing or how to take care of her daughter when she returns”
——————————————————————
I guess the National Heath Service oncologist is possibly like Gorski, and he doesn’t know what Burzynski is doing because he has NOT read Burzynski’s publications:
=====================================
7/22/2013

Critiquing: In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor… :
https://stanislawrajmundburzynski.wordpress.com/2013/07/22/critiquing-in-which-orac-does-stanislaw-burzynski-propagandist-eric-merola-a-favor/
======================================
Gorski flabbergasts:
——————————————————————
“The report includes interviews with experts like Professor Richard Grundy of Nottingham Children’s Hospital”

“Grundy points out that Burzynski has not published the complete results of any of his phase II clinical trials”
——————————————————————
What Gorski does NOT point out, is that for being a supposed “expert”, he sure does NOT give the impression that he’s taken the time to read Burzynski’s 2003-2010 phase II (2) clinical trials preliminary reports, in order to qualify as an “expert” on anything related to Burzynski

Gorski continues on as is his custom of being long-winded without much in the way of results:
——————————————————————
” … how Burzynski has abused the clinical trial process to keep treating patients with antineoplastons without actually having to do the science that any other doctor would be required to do to validate a new treatment”
——————————————————————
However, Gorski FAILS to address these issues:
======================================
WHAT IS MISDIRECTION? Critiquing “Antineoplastons: Has the FDA kept its promise to the American people ?”:
https://stanislawrajmundburzynski.wordpress.com/2013/06/08/what-is-misdirection-critiquing-antineoplastons-has-the-fda-kept-its-promise-to-the-american-people/
======================================
Gorski marches onward, jackbooted:
——————————————————————
“Dr. Elloise Garside, a research scientists, echoes a lot of the questions I have, such as how Burzynski never explains which genes are targeted by antineoplastons, what the preclinical evidence supporting their efficacy are, or what the scientific rationale is to expect that they might have antitumor activity”

“(Yes, we’re talking prior plausibility, baby!)”
——————————————————————
So, Gorski is saying that Dr. Elloise Garside has something in common with the “expert”, Professor Richard Grundy

Gorski rants on:
——————————————————————
“The preponderance of evidence supports the contention that they dont’ work, but there is uncertainty, which Burzynski exploits to the max”
——————————————————————
Amazing !!!

The United States Food and Drug Administration has authorized phase III (3) clinical trials, which means:
======================================
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”

“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
======================================
Burzynski: The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-the-fdas-drug-review-process-ensuring-drugs-are-safe-and-effective/
======================================
Gorski then blesses us with:
——————————————————————
” … the claims in some of the Q&A’s after screenings of Eric Merola’s most recent movie that Burzynski’s papers have been rejected without being sent out for peer review”

“Studies submitted to journals won’t be published without going out for peer-review”

“Maybe he’s referring to some of the papers we’ve heard about from Mr. Cohen and others that were editorially rejected and not even sent out for peer review because the editor either didn’t think them appropriate or didn’t want to waste the reviewers’ time”
——————————————————————
Gorski, who did a “review” of Burzynski: Cancer Is Serious Business, Part II (2), 6/3/2013, somehow magically “forgets” the very next day, that the documentary indicates that Burzynski submitted a phase II (2) clinical trial for publication, and was refused in 2 hours 8 minutes and 51 seconds, and Gorski is as silent as the dead about the lame reason given for NOT publishing it
======================================
See #12:
======================================
Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
======================================
How disingenuous, Gorski

Your opinion should mean

Nada

Zip

Zero

“Orac,” the false god continues on his rampage:
——————————————————————
“In science, all that matters is what you publish, and Burzynski hasn’t published anything other than case reports, tiny case series, and unconvincing studies, mostly (at least over the last decade or so) in crappy journals not even indexed on PubMed”
——————————————————————
Gorski gives NO reason for NOT doing what I have done on my blog, or any relevance of a publication NOT being listed on PubMed:
======================================
The #Burzynski B.S. App:
https://stanislawrajmundburzynski.wordpress.com/2013/06/06/the-burzynski-b-s-app-2/
======================================
Gorski comes to what he must think is his penultimate moment:
——————————————————————
“Without a doubt, the most effective part of the story is the segment in which Dr. Jeanine Graf of the Texas Children’s Hospital is introduced”

“Dr. Graf is the director of the pediatric intensive care unit there and has taken care of lots of Burzynski patients, as her hospital is “just down the road” from the Burzynski Clinic and these unfortunate children are brought to her hospital when they decompensate”

“Particularly damning is how Ms. Petagine said that the Texas Children’s Hospital Staff “were always cleaning up Burzynski’s messes.””

“If there’s one thing Panorama did right in this report, it’s showing how seeing so many already dying children show up in our ICU because of hypernatremia due to antineoplaston therapy will do that”
——————————————————————
Again, Gorski FAILS to discuss:
======================================
Burzynski: HYPERNATREMIA:
https://stanislawrajmundburzynski.wordpress.com/2013/04/24/burzynski-hypernatremia/
======================================
And:
——————————————————————
“Perhaps the most devastating part of this segment was seeing Dr. Graf stating, point blank, that she’s never seen a Burzynski patient survive”
——————————————————————
What is REALLY “devastating” is that Gorski is NOT able to indicate exactly how MANY patients this allegedly applies to, because, whereas Gorski’s fave reporter, Richard Bilton, wants to know how many Burzynski patients were treated in the phase II (2) clinical trials, he acts like Gorski’s “bud”, Dr. Peter A. Lipson, who also has had “issues” with consistency
======================================
Dr. Peter A. Lipson (and / or his Censor(s)) is a Coward: Critiquing “A Film Producer, A Cancer Doctor, And Their Critics”:
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/dr-peter-a-lipson-and-or-his-censors-is-a-coward-critiquing-a-film-producer-a-cancer-doctor-and-their-critics/
======================================
Gorski then rattles off:
——————————————————————
“Burzynski smirks when asked how many patients he’s treated and how many have survived, dodging the question by saying that the FDA won’t let him until he’s published his results”

“Bilton tells him that’s not true; the FDA has told him that Burzynski can tell him as long as he doesn’t promote antineoplastons”

“Burzynski asks Bilton why he doesn’t have a letter from the FDA”
——————————————————————
If Gorski had bothered to read all the comments I posted on his blog re my Burzynski research, he would know that Burzynski has every right to be wary

But Gorski’s arrogance, dismissiveness, and condescension make him his own worst enemy

He then faceplants:
——————————————————————
“Burzynski then promises that antineoplastons will be approved “soon””

“(they almost certainly won’t)”
——————————————————————
I guess Gorski can now see the future, and is all-knowing and omnipotent

But then again, “Orac” is god

“god” goes on to say:
——————————————————————
“Ultimately, the Burzynski Clinic did release some results, stating that 776 patients with brain tumors were treated in trials and that 15.5% have survived five years”

“Of course, this is an utterly meaningless factoid”

“because we don’t know what kinds of tumors, what gradess, how they were treated beforehand, or any other confounding factors”
——————————————————————
But this is because Gorski prefers NOT to pay attention; welcome to “Short Attention Span Theatre”, or seeming to NOT read Burzynski’s publications:
======================================
Colorado Public Television – PBS:
https://stanislawrajmundburzynski.wordpress.com/2013/03/09/colorado-public-television-pbs/
======================================
My Critique of Bob Blaskiewicz (Colorado Public Television – PBS CPT12):
https://stanislawrajmundburzynski.wordpress.com/2013/03/26/my-critique-of-bob-blaskiewicz-colorado-public-television-pbs-cpt12/
======================================
Gorski posted comments on the Colorado Public Television (PBS) (CPT12) Facebook page where this was posted:
======================================

======================================
6/5/2013 Gorski continued his blatherskite:
——————————————————————
Odds and ends left over after the Panorama Burzynski Clinic report: Burzynski versus his own SEC filing
http://scienceblogs.com/insolence/2013/06/05/odds-and-ends-about-burzynski-clinic/
——————————————————————
This is where I start leading to heapin’ helpings of not-so-Respectful Insolence

Gorski posts:
——————————————————————
“(stay classy, Stash, stay classy)”
——————————————————————
I am NOT positive as to why a LIAR would advise Burzynski to “stay classy” when he has absolutely NO moral or ethical standing to do so

The proverbial “pot calling the kettle, black”

Gorski blathers:
——————————————————————
” … in January the Burzynski Clinic removed all references to antineoplaston therapy on its website … “
——————————————————————
As I stated up top, Gorski must have his computer set so that it will NOT access Burzynski’s website, since I posted this:
======================================
3/12/2013

Burzynski updates Scientific Publications page:
https://stanislawrajmundburzynski.wordpress.com/2013/03/12/burzynski-updates-scientific-publications-page/
======================================
This includes the link to Burzynski’s ANTINEOPLASTON publications, which Gorski claims do NOT exist on Burzynski’s website

Perhaps this helps explain Gorski’s lack of knowledge re antineoplastons

Gorski admits:
——————————————————————
“Now I’m not a businessman, and I don’t understand anything but the very basics of business”
——————————————————————
But then goes on to claim:
——————————————————————
“but I do know cancer science”
——————————————————————
Gorski goes on to comment on material which I posted on his blog

Comment #128 Didymus Judas Thomas

At the Tu-Quack Center Correcting Orac’s EPIC & Legendary Research

February 2, 2013
http://scienceblogs.com/insolence/2013/01/21/quoth-joe-mercola-i-love-me-some-burzynski-antineoplastons/
“Yet in the report, we read:”
——————————————————————
On February 23, 2010, the Company entered into an agreement with Cycle Solutions, Inc., dba ResearchPoint (“Research Point”) to initiate and manage a pivotal Phase III clinical trial of combination Antineoplastons A10 and AS2-1 plus radiation therapy (RT) in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma”
——————————————————————
It’s good to see that in JUNE, Gorski is finally catching up to what I posted on his blog in FEBRUARY

Gorski goes on to comment:
——————————————————————
“Of course, given that after three years the clinical trial hasn’t been opened, more than likely no reputable institution wants to partner with the Burzynski Research Institute, and ResearchPoint collected its checks”
——————————————————————
This is the same Gorski who allegedly blogged about the documentary which covered this issue, which he “supposedly” did a“review” on

Gorski, who above claimed that he does NOT understand “business”, suddenly puts on his “lawyer” hat
——————————————————————
“There’s a lot of legalese and FDA bureau-speak, but the meaning should be fairly clear to a layperson”:

“Indeed, even the report seems to concede that antineoplastons will likely never be approved, even going so far to point out that “the Company cannot predict if and/or when it will submit an NDA [New Drug Application] to the FDA, nor can the Company estimate the number or type of additional trials the FDA may require.””

“Burzynski also warns that “there can be no assurance that an NDA for Antineoplastons, as a treatment for cancer, will ever be approved by the FDA.””

“That hardly sounds as though antineoplastons will be approved “soon.””
——————————————————————
I find it remarkable that Gorski, while admitting above that he does NOT understand
“business”, seemingly expects the reader to believe that he understands “legalese”

Gorski bounds on in his new found knowledge as a “legal mastermind”:
——————————————————————
“Another interesting tidbit in the SEC filing is Burzynski’s report of the results of several of his clinical trials”

“They aren’t really “results’ per se, in that the information presented really isn’t provided in a form that really allows other investigators to evaluate it and potentially replicate it”

“Basically it’s a big table listing Burzynski Research Institute clinical trials and response rates reported”

“One thing that I noticed right away is that in most trials, the number of evaluable patients is smaller, sometimes much smaller, than the number of patients accrued”

“This is a huge red flag”

“For instance, in trial BT-20, there were 40 patients accrued by only 22 were evaluable”

“This sort of dropoout rate is a huge red flag”

“We don’t know the reasons for this dropout rate”

“It could certainly skew the results, but even that’s impossible to tell from just a table of response rates and no further information”
� � � � � � � � � � � � � � � �
The ONLY “HUGE RED FLAG” is how inept Gorski is
� � � � � � � � � � � � � � � �
Gorski, you’re no Craig Masilow, but you are a LIAR
� � � � � � � � � � � � � � � �
I’ve done the 1st one for you
======================================
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf

Pg. 96

2 patients unable to be evaluated

patient 2 didn’t have follow-up MRI to determine response

patient 11 died of intratumoral hemorrhage and duration of treatment too short for evaluation of response
======================================
http://www.burzynskiclinic.com/images/stories/Publications/970.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/994.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/1145.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/1146.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/1147.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/1220.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/1252.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/2105.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/7287.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/7853.pdf


=====================================
http://www.burzynskiclinic.com/images/stories/Publications/7898.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/8397.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/8637.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/8638.pdf


======================================
http://www.burzynskiclinic.com/images/stories/Publications/8639.pdf


======================================
And THIS is the Gorski who has claimed to have reviewed almost all of Burzynski’s antineoplaston publications
======================================
11/2/2012

“Personally, having pored over Burzynski’s publications … “
http://scienceblogs.com/insolence/2012/11/02/stanislaw-burzynski-fails-to-save-another-patient/
======================================
5/8/2013

“I’ve searched Burzynski’s publications … “
http://scienceblogs.com/insolence/2013/05/08/eric-merola-and-stanislaw-burzynskis-secret-weapon-against-the-skeptics-fabio-lanzoni-part-2/
======================================

WHAT IS MISDIRECTION? Critiquing “Antineoplastons: Has the FDA kept its promise to the American people ?”

March 29, 1996

Then United States Food and Drug Administration Commissioner, David Kessler told the American people:

1. We will eliminate unnecessary paperwork … that used to delay or discourage … cancer research … by non-commercial clinical investigators

2. The … FDA’s initiatives … will allow …the agency … to rely on smaller trialsfewer patients … if there is evidence … of partial response in clinical trials

I don’t want to get into any particular … agent … except let me point out … that … the information needs to be part … of clinical trials

3. We will accept … less informationup front

4. we’re going to require further study AFTERapproval … because the science … has matured

5. The important – point … is that information needs to be gathered … through scientific means … through clinical – trials … and I think – that’s … that’s very important uhh very … important point

You can’t … just … use an agent here – or there … you have to use it … as part of a clinical trial … so we can get information … on whether the drug works

6. The uhh agency has … many … trials … has has approved trials … for patients … with antineoplastons

7. We are committed to providing expanded access … availability … for American patients for any drug … there’s reason to believe … may work
——————————————————————
BOTTOM LINE:
——————————————————————
Everything else is MISDIRECTION
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/22/antineoplastons-has-the-fda-kept-its-promise-to-the-american-people
——————————————————————
A. What is the FDA’s definition of “unnecessary paperwork”?

B. What is the FDA’s definition of “smaller trials”?

C. What is the FDA’s definition of “fewer patients”?

D. What is the FDA’s definition of “evidence … of partial response“?

E. What is the FDA’s definition of “less information … up front”?

F. What is the FDA’s definition of “we’re going to require further study AFTER … approval”?

G. What is the FDA’s definition of “We are committed to providing expanded access … availability … for American patients for any drug … there’s reason to believe … may work”?
======================================
2003 – 2009 Phase II preliminary
——————————————————————
2003 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101
(Drugs in R and D / Drugs in Research and Development)

2003: Protocol – recurrent diffuse intrinsic brain stem glioma

12 – Patients Accrued
10 – Evaluable Patients

2 / 20% – # and % of Patients Showing Complete Response
3 / 30% – # and % of Patients Showing Partial Response
3 / 30% – # and % of Patients Showing Stable Disease
2 / 20% – # and % of Patients Showing Progressive Disease
======================================
http://www.burzynskiclinic.com/scientific-publications.html
Interim Reports on Clinial Trials:

1. 10/2003

NEURO-ONCOLOGY

Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I.

Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive MULTICENTRIC GLIOMA

A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/970.pdf
Neuro-Oncology. 2003; 5: 358
Volume 5 Issue 4 October 2003

10/2003 – Protocol – MULTICENTRIC GLIOMA

12 – Children Patients Accrued
10 – Evaluable Patients
(9 months-17 years / 9 – median age)

4 / 33% – # and % of Patients Showing Complete Response
2 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
1 / 9% – # and % of Patients Nonevaluable due to only 4 weeks of treatment / lack of follow-up scans
======================================
Interim Reports on Clinial Trials:

16. 2003

DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)

BT-11
BRAIN STEM GLIOMA

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA:

a preliminary report.
http://www.ncbi.nlm.nih.gov/pubmed/12718563
Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M.
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf

Pgs. 91-92 and 95

3/1996 – Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled / Pg. 94)

12 – Patients Accrued (6 males / 6 females)
(4-29 years / 10 – median age)
10 – Evaluable Patients

2 / 20% – # and % of Patients Showing Complete Response
3 / 30% – # and % of Patients Showing Partial Response
3 / 30% – # and % of Patients Showing Stable Disease
2 / 20% – # and % of Patients Showing Progressive Disease
======================================
2004 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26
(Drugs in R and D / Drugs in Research and Development)

2004: Protocol – incurable recurrent and progressive multicentric glioma

12 – Patients Accrued
(9 – median age)
11 – Evaluable Patients

4 / 33% – # and % of Patients Showing Complete Response
3 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

2. 10/2004

NEURO-ONCOLOGY

BT-20
Patients With GLIOBLASTOMA MULTIFORME (GBM)

Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V.

Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent GLIOBLASTOMA MULTIFORME
http://www.burzynskiclinic.com/images/stories/Publications/1218.pdf
Neuro-Oncology. 2004; 6: 384
Volume 6 Issue 4 October 2004
Abstracts from the Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004

Pg. 385

10/2004 – Protocol – glioblastoma multiforme (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy

22 – Evaluable Patients
(6 men / 16 women / 27-63 /47 – median age)

1 / 4.5% – # and % of Patients Showing Complete Response
1 / 4.5% – # and % of Patients Showing Partial Response
12 / 54.5% – # and % of Patients Showing Stable Disease
8 / 36.5% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

3. 10/2004 (DBSG)

NEURO-ONCOLOGY

Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.

Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic BRAIN STEM GLIOMA
http://www.burzynskiclinic.com/images/stories/Publications/1219.pdf
Neuro-Oncology. 2004; 6: 386
Volume 6 Issue 4 October 2004

60 patients
(31 didn’t meet admission criteria to the study and were treated under Special Exception (SE))

10/2004 – Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG)

29 – Evaluable Patients

7 / 24% – # and % of Patients Showing Complete Response
6 / 21% – # and % of Patients Showing Partial Response
6 / 21% – # and % of Patients Showing Stable Disease
10 / 34% – # and % of Patients Showing Progressive Disease
——————————————————————
31 – Evaluable Patients: Special exception (SE)

5 / 16% – # and % of Patients Showing Complete Response
2 / 6% – # and % of Patients Showing Partial Response
16 / 52% – # and % of Patients Showing Stable Disease
8 / 26% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

4. 10/2004 (AT/RT of CNS)

NEURO-ONCOLOGY

BT-14

CHILDREN WITH RHABDOID TUMOR OF THE CENTRAL NERVOUS SYSTEM

Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.

Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system

A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/1146.pdf
Neuro-Oncology. 2004; 6: 427
Volume 6 Issue 4 October 2004
Abstracts from the Eleventh International Symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16, 2004

10/2004 – Protocol – children with atypical teratoid / rhabdoid tumors (AT / RT) of the central nervous system

11 – Children Patients Accrued
8 – Evaluable Patients
(7 treated under Special Exception (SE))

2 / 25% – # and % of Patients Showing Complete Response
1 / 12.5% – # and % of Patients Showing Partial Response
1 / 12.5% – # and % of Patients Showing Stable Disease
4 / 50% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

5. 10/2004

NEURO-ONCOLOGY

BT-12

CHILDREN WITH PRIMITIVE NEUROECTODERMAL TUMORS (PNET)

Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.

Treatment of PRIMITIVE NEUROECTODERMAL TUMORS (PNET) with antineoplastons A10 and AS2-1 (ANP)

Preliminary results of phase II studies
http://www.burzynskiclinic.com/images/stories/Publications/1147.pdf
Neuro-Oncology. 2004; 6: 428
Volume 6 Issue 4 October 2004
Abstracts from the Eleventh International Symposium on Pediatric Neuro-Oncology

10/2004 – Protocol – PRIMITIVE NEUROECTODERMAL TUMORS (PNET)

17 – Patients Accrued
15 – Evaluable Patients
(12 months – 23 years / 6 – median age)

3 / 20% – # and % of Patients Showing Complete Response
2 / 13.4% – # and % of Patients Showing Partial Response
5 / 33.3% – # and % of Patients Showing Stable Disease
5 / 33.3% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

17. 2004

DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)

Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma.

A Preliminary Report.
http://www.ncbi.nlm.nih.gov/pubmed/15563234
Drugs R&D 2004;5(6):315-326.
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf

incurable recurrent and progressive multicentric glioma

Pg. 320

3 – treated under Special Exception (SE) granted by the US FDA

Pgs. 317 and 320

7/31/1996 – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive multicentric glioma (MCG)

Pg. 317

BT-13

children with low-grade astrocytoma

BT-23

children with visual pathway gliomas


Pgs. 317 and 320-321

12 – Children Patients Accrued (Pgs. 315-316)
(9 months – 17 years / 9- median age)
(6 – male / 6 – females)
10 – Evaluable Patients (Pg. 315)

4 / 33% – # and % of Patients Showing Complete Response
3 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
1 / 9% – # and % of Patients Non-evaluable
——————————————————————
Pg. 325

Compare: Chamberlain and Grafe. [38]

1995 – Protocol – solitary recurrent chiasmatic hypothalamic gliomas treated with oral etoposide


14 – Patients Accrued
14 – Evaluable Patients

1 / 7% – # and % of Patients Showing Complete Response
4 / 29% – # and % of Patients Showing Partial Response
3 / 21% – # and % of Patients Showing Stable Disease
6 / 43% – # and % of Patients Showing Progressive Disease

Pg. 326

38. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995; 13: 2072-6
http://www.ncbi.nlm.nih.gov/pubmed/7636550/
J Clin Oncol. 1995 Aug;13(8):2072-6.
http://www.ncbi.nlm.nih.gov/m/pubmed/7636550/
Department of Neurosciences, University of California, San Diego, La Jolla, USA.
http://m.jco.ascopubs.org/content/13/8/2072.long
Arch Neurol. 1995 May;52(5):509-13.
http://www.ncbi.nlm.nih.gov/pubmed/7733847/
Department of Neurosciences, University of California-San Diego, USA.
http://www.ncbi.nlm.nih.gov/m/pubmed/7733847/
Arch Neurol. 1995;52(5):509-513. doi:10.1001/archneur.1995.00540290099024.
http://archneur.jamanetwork.com/Mobile/article.aspx?articleid=593460
——————————————————————
Compare: The Pediatric Oncology Group. [39]

10/2000 – Protocol – solitary progressive optic pathway tumors with carboplatin

50 – Patients Accrued
50 – Evaluable Patients

2 / 4% – # and % of Patients Showing Partial Response
37 / 74% – # and % of Patients Showing Stable Disease
11 / 22% – # and % of Patients Showing Progressive Disease

39. Mahoney DH, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-oncol 2000; 2: 213-20
http://www.ncbi.nlm.nih.gov/pubmed/11265230/
Neuro Oncol. 2000 Oct;2(4):213-20.
http://www.ncbi.nlm.nih.gov/m/pubmed/11265230/
Baylor College of Medicine, Houston, TX, USA.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920597/

http://neuro-oncology.oxfordjournals.org/content/2/4/213.full.pdf
======================================
2005 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77
(Integrative Cancer Therapies)

2005: Protocol – recurrent disease or high risk

13 – Patients Accrued
(1-11 – age / 5 years 11 months – median age)
13 – Evaluable Patients

3 / 23% – # and % of Patients Showing Complete Response
1 / 8% – # and % of Patients Showing Partial Response
4 / 31% – # and % of Patients Showing Stable Disease
5 / 38% – # and % of Patients Showing Progressive Disease
——————————————————————
(Updated 2007)
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
2005 – Protocol – incurable recurrent and progressive multicentric glioma

13 – Patients Accrued

3 / 23% – # and % of Patients Showing Complete Response
1 / 8% – # and % of Patients Showing Partial Response
4 / 31% – # and % of Patients Showing Stable Disease
5 / 38% – # and % of Patients Showing Progressive Disease
======================================
2006 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
(Integrative Cancer Therapies)

2006: Protocol – high-grade pathology (HBSG)

– Patients Accrued
18 – Evaluable Patients

2 / 11% – # and % of Patients Showing Complete Response
2 / 11% – # and % of Patients Showing Partial Response
7 / 39% – # and % of Patients Showing Stable Disease
7 / 39% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

BT-03


BT-11

BRAIN STEM GLIOMA (BSG)

BT-18

6. MIXED GLIOMA

ADULT PATIENTS WITH MIXED GLIOMA

“mixed glioma”, a type of primary malignant brain tumor (PMBT)

BT-22

8. CHILDREN WITH PRIMARY MALIGNANT BRAIN TUMORS

CAN-01 (CAN-1)

PATIENTS WITH REFRACTORY MALIGNANCIES

19. 3/2006

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive BRAINSTEM GLIOMA. Integrative Cancer Therapies 2006;5(1):40-47
http://www.ncbi.nlm.nih.gov/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
DOI: 10.1177/1534735405285380
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf

http://m.ict.sagepub.com/content/5/1/40.long?view=long&pmid=16484713
Pgs. 40-41

4 phase 2 trials

BRAINSTEM GLIOMA (BSG)

patients with inoperable tumor of high-grade pathology (HBSG)
glioblastoma

recurrent diffuse intrinsic glioblastomas and ANAPLASTIC ASTROCYTOMAs of brainstem

Pg. 43

BT-03 – 1 / female
BT-11 – 13 (8 males/5 females)
BT-18 – 1 / female
BT-22 – 2 / females
CAN-01 – 1 / female

Pg. 44

High-grade, recurrent, and progressive brainstem gliomas

Pgs. 40-42 and 44-45

7/12/1988 (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem high-grade pathology (HBSG)

18 – Evaluable Patients (Pgs. 40-43)
(8 males / 10 females / 2-42 / 10 – median age / Pgs. 42-43)

2 / 11% – # and % of Patients Showing Complete Response
2 / 11% – # and % of Patients Showing Partial Response
7 / 39% – # and % of Patients Showing Stable Disease
7 / 39% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

BT-11

BRAIN STEM GLIOMA

8. 10/2006

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V. Treatment of multicentric BRAINSTEM GLIOMAs with antineoplastons (ANP) A10 and AS2-1. Neuro-Oncology. 2006; 8:466.
http://www.burzynskiclinic.com/images/stories/Publications/2105.pdf
Volume 8 Issue 4 October 2006
Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO)

Brainstem gliomas and multicentric tumors (MBSG)

10/2006 – Protocol – Brainstem gliomas and multicentric tumors (MBSG)

19 – Evaluable Patients
3.9 – 40.8 years (9.2 – median age)
(90% less than 18 years old)

2 / 11% – # and % of Patients Showing Complete Response
1 / 5% – # and % of Patients Showing Partial Response
7 / 37% – # and % of Patients Showing Stable Disease
9 / 47% – # and % of Patients Showing Progressive Disease
======================================
2007
http://www.burzynskiclinic.com/images/stories/Publications/1252.pdf
2004 – Protocol – small group of patients with progressive LGA, ANP
60% – % of Patients Showing Complete Response
10% – % of Patients Showing Partial Response
——————————————————————
2004 – Protocol – low-grade astrocytoma in children
Burzynski [39] – Reference
Phase II d – d = Preliminary results – Study type
P – P = progressive tumor – Tumor type
(no. of pts) – pts = patients
ANP (10) – ANP = antineoplastons A10 and AS2-1 – Treatment
10 – Evaluable Patients {(78) = most in a study}
OS [%] – OS = overall survival
100% (1 yr) – 90% (3 yr) – Efficacy
93 mo – MST = MST = median survival time – {96 (1 y) next closest}
60% (6) – % and # of Patients Showing Complete Response {24 (11) next closest}
10% (1) – % and # of Patients Showing Partial Response {60% (9) best other study}
30% (3) – % and # of Patients Showing Stable Disease + MR = minor response {70% (14) best other study}
0% (0) – % and # of Patients Showing Progressive Disease {4% (2) next closest}
PFS (%)
90 (1 y) – 90 (3 y) – PFS = progression-free survival {100 (1 y) – 68 (3 y) best other study
——————————————————————
2004 – Protocol – diffuse, intrinsic brainstem glioma in children
Burzynski et al. [88] – Reference
Phase II – Study Type
(no. of pts) – pts = patients
RP (30) – RP = recurrent and progressive tumor – Tumor type
30 – Evaluable Patients
ANP – ANP = antineoplastons A10 and AS2-1 – Treatment – ANP
OS (%) – OS = overall survival
[2y; 5y]
46.7; 30 – Efficacy
MST (mo)
19.9 – MST = median survival time
27% (8) – % and # of Patients Showing Complete Response
20% (6) – % and # of Patients Showing Partial Response
23% (7) – % and # of Patients Showing Stable Disease
30% (9) – % and # of Patients Showing Progressive Disease
——————————————————————
Burzynski et al. [89] – Reference
Phase II – Study Type
(no. of pts) – pts = patients
RPS (10) – RPS = recurrent and progressive tumors in children aged <4y – Tumor type {(66) = most in a study}
ANP – ANP = antineoplastons A10 and AS2-1 – Treatment – ANP
OS (%) – OS = overall survival
[2y; 5y] – Efficacy
60; 20 {46.7 (30) = next best study}
MST (mo)
26.3 – MST = median survival time – {19.9 = next best study}
[% (no. )]
30% (3) – CR = complete response – {27% (8) = next best study}
[% (no. )]
0% (0) – PR = partial response – {56% (1) = next best}
[% (no. )]
40% (4) – SD = stable disease – {44% (25) = best}
[% (no. )]
30% (3) – PD = progressive disease – {23% (13) = best}
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:

BT-11

BRAIN STEM GLIOMA

9. 4/2007 (NDBSG)

Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs. Neuro-Oncology 2007; 9:206.
http://www.burzynskiclinic.com/images/stories/Publications/4021.pdf
Volume 9 Issue 2 April 2007
Abstracts from the Twelfth International Symposium on Pediatric Neuro-Oncology

4/2007 – Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG)

20 – Evaluable assessable children Patients
(3 months-20 years – age)

6 / 30% – # and % of Patients Showing Complete Response
2 / 10% – # and % of Patients Showing Partial Response
4 / 20% – # and % of Patients Showing Stable Disease
8 / 40% – # and % of Patients Showing Progressive Disease
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:

BT-11

BRAIN STEM GLIOMA

Special exception (SE)

13. 12/2009 (DBSG)

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with BRAINSTEM GLIOMA. Protocol BC-BT-11. Neuro-Oncology 2009, 11:951.
http://www.burzynskiclinic.com/images/stories/Publications/8639.pdf
Volume 11 Issue 6 December 2009
Abstracts from the Third Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and the Sixth Meeting of the Asian Society for Neuro-Oncology (ASNO)
May 11-14, 2009
Yokohama, Japan

12/2009 – Protocol – BRAINSTEM GLIOMAs

40 – Patients Accrued
28 – Evaluable Patients
(23 children / 5 young adults)

5 / 18% – # and % of Patients Showing Complete Response
4 / 14% – # and % of Patients Showing Partial Response
12 / 43% – # and % of Patients Showing Stable Disease
7 / 25% – # and % of Patients Showing Progressive Disease
——————————————————————
Special exception (SE)

12/2009 – Protocol – BRAINSTEM GLIOMAs

52 – Evaluable Patients
(40 children / 12 young adults)

5 / 10% – # and % of Patients Showing Complete Response
2 / 4% – # and % of Patients Showing Partial Response
28 / 54% – # and % of Patients Showing Stable Disease
17 / 32% – # and % of Patients Showing Progressive Disease
——————————————————————
BT-11 and special exception (SE)
92% – diffuse intrinsic brainstem gliomas (DBSG)

Overall survival (OS) – 2 years:
42% – special exception (SE)
36% – BT-11

Overall survival (OS) – 5 years:
19% – special exception (SE)
25% – BT-11
======================================
Compare: standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al. 1999)

2% – % of Patients Showing Complete Response
31% – % of Patients Showing Partial Response

Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brain stem tumors: results of pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:959-964.
http://www.ncbi.nlm.nih.gov/pubmed/10192340/
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64.
http://www.ncbi.nlm.nih.gov/m/pubmed/10192340/
International Journal of Radiation Oncology*Biology*Physics
Volume 43, Issue 5, 15 March 1999, Pages 959–964
http://www.sciencedirect.com/science/article/pii/S036030169800501X
Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY, USA.
6/1992 – 10/1997

Overall survival (OS):
7% – 2 years
0% – 5 years
=====================================
COMBINED:
——————————————————————
Overall survival (OS) – 2 years:
——————————————————————
42% – antineoplastons: special exception (SE)

36% – antineoplastons: BT-11

7% – standard radiation therapy in combination with chemotherapy (RAT)
——————————————————————
Overall survival (OS) – 5 years:
——————————————————————
25% – antineoplastons: BT-11

19% – antineoplastons: special exception (SE)

0% – standard radiation therapy in combination with chemotherapy (RAT)
� � � � � � � � � � � � � � � � �
Break The Walls Down:

——————————————————————
And “THAT’s The BOTTOM LINE”
Because Stone Cold Said So

——————————————————————
IT’s GO TIME
Time To Play The Game:

——————————————————————
Break The Walls Down:

=====================================

IT MAY NOT BE SCIENCE: Critiquing “Curing cancer or ‘selling hope’ to the vulnerable?”

Recently, America was warned again:

“The British Are Coming”

“The British Are Coming”

Yes, Mr. and Mrs. America and all the Ships at SEA,
We were “blessed” with a visit from the “Bloody Well Right,” Panorama BBC
http://t.co/nFpwlQg275
By Richard Bilton
http://t.co/IY53fEpnBu
BBC Panorama
3 June 2013 Last updated at 00:03

As luck would have it, as I was researching my Critique for this article, BBC Panorama provided me with the title for it, in their YouTube Video:

“IT MAY NOT BE SCIENCE”

This was apropo since it quite possibly defines the entire Panorama article in a “nutshell’

The article states:

“But Dr Stanislaw Burzynski’s treatment has been dismissed by practitioners of mainstream medicine.”

From this, I take it that the viewer is supposed to conclude that the

“practitioners of mainstream medicine”

are:

1. Prof Richard Grundy

and

2. Dr Jeanine Graf

Let’s examine their claims, shall we?

1. Prof Richard Grundy

A. “He says it is “unethical” for Dr Burzynski not to share his findings:”

In my ‘opinion,’ it is “unethical” for Professor Grundy to throw MUD at Dr. Burzynski, when he has NOT shared his findings re Dr. Burzynski’s:

Drugs In R and D / Drugs in Research and Development:

Drugs R D. 2003;4(2):91-101
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2004;5(6):315-26
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Integrative Cancer Therapies

Integr Cancer Ther. 2005 Jun;4(2):168-77
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
2007
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html

B. “Unfortunately the results from Dr Burzynski’s clinic are not published in any form that’s acceptable to the scientific community.”

Professor Grundy, welcome to #MizTV

really?Really??REALLY???

Please expound

and

2. Dr Jeanine Graf

“She sometimes treats patients from the Burzynski Clinic who have become critically ill, but she has never known any of them survive.”

Dr. Graf, how many patients?

2 ?

“He must believe in what he’s doing, but I have not been convinced by the existing scientific literature that his therapy has any efficacy.

Dr. Graf, where is your “in-depth” review of Dr. Burzynski’s above-listed publications?

Dr. Graf, please provide your in-depth “opinion” on this:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-the-fdas-drug-review-process-ensuring-drugs-are-safe-and-effective/
“But the more I looked, the more complicated the picture became.”

“I was shown into the boardroom and, after 20 minutes waiting, the doctor was ready to see me.”

Mr. Bilton, I am sure that how long you had to spend waiting, might be important to you, but to the viewers:

Not So Much

This might be classified as a human interest story, but YOU are NOT the human whose story we are interested in

“He said the medical authorities in the US would not let him release this information:”

“Clinical trials, phase two clinical trials, were completed just a few months ago. I cannot release this information to you at this moment.”.

“But the FDA told us this was not true and he was allowed to share the results of his trials.”

I’m sure that after perusing the below, that you will be able to come to the conclusion that there are “trust” issues involved, so Dr. Burzynski is correct to be concerned

Burzynski: Managing social conflict in complementary and alternative medicine research: the case of antineoplastons:
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-managing-social-conflict-in-complementary-and-alternative-medicine-research-the-case-of-antineoplastons/
Antineoplastons: Has the FDA kept its promise to the American people ?
https://stanislawrajmundburzynski.wordpress.com/2013/03/22/antineoplastons-has-the-fda-kept-its-promise-to-the-american-people/
Cancer: Hope for Sale? will be broadcast on Monday, 3 June at 20:30 BST on BBC One

BBC One – Panorama, Cancer: Hope for Sale?

Panorama prog on #Burzynski is there for posterity on YouTube
http://t.co/YOlSjCg1d0
BBC Panorama Burzynski investigation on Youtube
http://t.co/6cDJapt6eM
THIS IS IT!
Our debut on the BBC’s Panorama. I hope this reaches millions!!! SO Burzynski will be deprived of…
http://fb.me/LYCqmKrh
“On Panorama tonight

“The doctor who says that he can cure cancer

The Burzynski clinic says it doesn’t claim it can cure all cancers and that no patients are promised a cure.
https://stanislawrajmundburzynski.wordpress.com/2013/06/04/the-british-are-coming-the-british-are-coming-critiquing-curing-cancer-or-selling-hope-to-the-vulnerable/
Make up your mind, Panorama

The British are Coming, The British are Coming: Critiquing “Curing cancer or ‘selling hope’ to the vulnerable?”

By Richard Bilton
http://t.co/nFpwlQg275
BBC Panorama

3 June 2013 Last updated at 00:03

“Legal loophole”

“Dr Burzynski exploits a legal loophole:”

“the patients treated with antineoplastons do so as part of a clinical trial, so the drug does not need a licence.”

I am truly impressed, and mightily so

Who knew that if “BBC Panorama” had just investigated Dr. Burzynski, years ago, we could have gotten this all out of the way, long ago

Yes, Mr. and Mrs. America, and all the ships at sea, BBC Panorama has decided the question for us, once and for all

Clinical Trials-are, get ready for it, wait for it, “Legal loopholes

WOW

I KNOW

Who woulda thunk THAT?

Thank goodness they couldn’t put the Concorde on their expense account

The British Are Coming

The British Are Coming

And Mumsie, can we keep them?

“These trials have been taking place for 20 years.”

It’s good to find out that someone can get close to “1994” when Dr. Burzynski’s Securities and Exchange (SEC) filings indicate 2 phase 2 clinical trials were in progress

Maybe some of “The Skeptics” are learning to read?

“Despite years of research, Dr Burzynski has never published full results.”

BBC Panorama (@BBCPanorama) would that be because the phase 2 clinical trials were NOT done?

Would “results” normally be published after the clinical trials are finished?

Brave Maverick Welsh Schoolboy frantically waves hand at back of classroom, as if to say: “Pick Me, … Pick Me

All in all, it’s just another “Brick” in the Wall

“If he has discovered a breakthrough, he is not sharing it with the rest of the world.”

Perhaps that’s what those pesky phase 2 clinical trials preliminary reports from 2003, 2004, 2005, 2006, etc., are all about, me little lad

“If you don’t eat your meat, you can’t have any pudding”

Yes

Laddie

“Divided doctors”

“Prof Richard Grundy treats children with cancer, and runs one of the UK’s biggest research projects into brain tumours.”

“He says it is “unethical” for Dr Burzynski not to share his findings:”

Does Professor Richard Grundy know what a phase 2 clinical trial preliminary report looks like, and does he know how to read?

“”I understand that that draw is very attractive.”

“Unfortunately the results from Dr Burzynski’s clinic are not published in any form that’s acceptable to the scientific community.””

Oh, my

I wish I could have been there in person to hear that

Did he have a British stiff upper lip when he said it?

Was one of his pinky fingers pointing straight up?

Do tell

Exactly what is:

published in any form that’s acceptable to the scientific community“?

Cancer: Hope for Sale? will be broadcast on Monday, 3 June at 20:30 BST on BBC One

BBC One – Panorama, Cancer: Hope for Sale?

“From the start I had wanted to meet Dr Burzynski.”

“He rarely gives interviews nowadays and he refused our original requests, but while I was in Houston I was told he would meet me.”

“His clinic is a mirror-fronted office block in one of Houston’s better areas.”

I’m sure the Houston Tourism Board and Convention Center was ecstatic to hear this ….the part about Houston having “better areas,” that is

“Next some basic facts – how many patients has he treated with antineoplastons, and how many have survived?”

“He said the medical authorities in the US would not let him release this information:”

“”Clinical trials, phase two clinical trials, were completed just a few months ago.”

“I cannot release this information to you at this moment.””

“But the FDA told us this was not true and he was allowed to share the results of his trials.”

Really, old chap

And exactly who at the FDA told you that?

Or is it a secret, … secret secret?

“Dr Burzynski left the interview angry, apparently affronted that his great discovery was questioned.”

Dr. Burzynski seems to have some difficulties with “little men

How tall are you?

And have you heard of one Craig Masilow and one Dr. David H. Gorski?

“They see him as a maverick, an outsider fighting the traditional medical establishment.”

He is a maverick in much the same was as Dr. David H. Gorski, and his revolutionary “glucose / sugar does NOT feed cancer” “Oracolytes

“The American Food and Drug Administration (FDA) and the Texas Medical Board have been battling Dr Burzynski for decades.”

Indeed

Do you have any idea of how many millions upon millions of United States Taxpayer Dollars were used to criminally pursue Dr. Burzynski, when they had a civil remedy available to them?

Do you think they put it on their resumes?

“The Burzynski clinic says it doesn’t claim it can cure all cancers and that no patients are promised a cure.”

“They say 776 patients with brain tumours were treated in trials before 2008.”

“And that 15.5% had survived more than five years, which compares favourably to other treatments.”

OH … MY … GOODNESS

Data

How did you get THAT?

Ask?

Or was it freely given?

“But it is harder to understand how Dr Burzynski has been able to sell his experimental treatment to the vulnerable for so many years.”

Did you ask your “chums,” the great people at the United States Food and Drug Administration?

Panorama, Cancer: Hope for Sale?, BBC One, Monday 3 June at 20:30 BST and then available in the UK on the BBC iPlayer.